[go: up one dir, main page]

MX2016013910A - Tratamiento del cancer. - Google Patents

Tratamiento del cancer.

Info

Publication number
MX2016013910A
MX2016013910A MX2016013910A MX2016013910A MX2016013910A MX 2016013910 A MX2016013910 A MX 2016013910A MX 2016013910 A MX2016013910 A MX 2016013910A MX 2016013910 A MX2016013910 A MX 2016013910A MX 2016013910 A MX2016013910 A MX 2016013910A
Authority
MX
Mexico
Prior art keywords
tumor
methods
cancer treatment
expression levels
positive cells
Prior art date
Application number
MX2016013910A
Other languages
English (en)
Other versions
MX375794B (es
Inventor
Francois Andre MARTINI Jean-
Christo Tarazi Jamal
Andrew Williams James
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016013910A publication Critical patent/MX2016013910A/es
Publication of MX375794B publication Critical patent/MX375794B/es

Links

Classifications

    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G01N33/575—
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Se describen métodos diagnósticos para predecir si un tumor humano es sensible al tratamiento con axitinib, y métodos de tratamiento de un tumor humano; los métodos se basan en la medición de los niveles de expresión del polipéptido de CD68 en una muestra de tejido de un tumor; los niveles de expresión de CD68 se pueden medir usando inmunohistoquímica, donde se puede determinar el porcentaje de células CD68 positivas y la densidad de células CD68 positivas dentro del tumor.
MX2016013910A 2014-04-24 2015-04-16 Axitinib para usarse en el tratamiento de cáncer de células renales metastásico. MX375794B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24
PCT/IB2015/052796 WO2015162532A1 (en) 2014-04-24 2015-04-16 Cancer treatment

Publications (2)

Publication Number Publication Date
MX2016013910A true MX2016013910A (es) 2017-01-11
MX375794B MX375794B (es) 2025-03-07

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013910A MX375794B (es) 2014-04-24 2015-04-16 Axitinib para usarse en el tratamiento de cáncer de células renales metastásico.

Country Status (23)

Country Link
US (2) US20170184602A1 (es)
EP (1) EP3134119B1 (es)
JP (1) JP6603474B2 (es)
KR (1) KR101943177B1 (es)
CN (1) CN106233143B (es)
AR (1) AR100169A1 (es)
AU (3) AU2015249513A1 (es)
BR (1) BR112016024143A2 (es)
CA (1) CA2946362C (es)
CY (1) CY1120731T1 (es)
DK (1) DK3134119T3 (es)
ES (1) ES2691213T3 (es)
HU (1) HUE040167T2 (es)
IL (1) IL247859B (es)
MX (1) MX375794B (es)
PL (1) PL3134119T3 (es)
PT (1) PT3134119T (es)
RU (1) RU2651469C1 (es)
SG (1) SG11201607918TA (es)
SI (1) SI3134119T1 (es)
TR (1) TR201815682T4 (es)
TW (1) TWI568439B (es)
WO (1) WO2015162532A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
CN112654365A (zh) 2018-07-12 2021-04-13 科尔沃斯制药股份有限公司 用于检测和治疗具有腺苷途径激活的癌症的方法
CA3106038A1 (en) * 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US11409549B2 (en) 2018-10-15 2022-08-09 AIble Inc. Interface for generating models with customizable interface configurations
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
US20220390456A1 (en) * 2019-10-17 2022-12-08 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
JP2025518483A (ja) * 2022-05-11 2025-06-17 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 肺癌のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用
JP2025518482A (ja) * 2022-05-11 2025-06-17 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 膵臓癌および２型糖尿病のための診断マーカーとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用
WO2024026407A1 (en) * 2022-07-28 2024-02-01 The Board Of Regents Of The University Of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004284434A1 (en) 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR assay system for gene expression profiling
DK2163650T3 (en) * 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20090221010A1 (en) * 2005-10-21 2009-09-03 Elting James J Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors
CN101512343A (zh) * 2006-07-28 2009-08-19 诺瓦提斯公司 黑素瘤抑制性活性蛋白（mia）作为在黑素瘤治疗性反应中的早期指示物的应用
US8338433B2 (en) * 2006-11-22 2012-12-25 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetoplastid agents
JP5773998B2 (ja) * 2009-07-08 2015-09-02 ワールドワイド・イノベイティブ・ネットワークＷｏｒｌｄｗｉｄｅ Ｉｎｎｏｖａｔｉｖｅ Ｎｅｔｗｏｒｋ 患者における薬物の有効性を予測する方法
MX2012002909A (es) * 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
JP2014503500A (ja) * 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
WO2013052652A1 (en) * 2011-10-04 2013-04-11 Erard Gilles Methods and systems for identifying and treating anti-progestin sensitive tumors
KR20140114415A (ko) 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커

Also Published As

Publication number Publication date
SI3134119T1 (sl) 2018-11-30
TWI568439B (zh) 2017-02-01
CY1120731T1 (el) 2019-12-11
PL3134119T3 (pl) 2018-12-31
IL247859B (en) 2020-07-30
KR101943177B1 (ko) 2019-01-28
JP2015210268A (ja) 2015-11-24
JP6603474B2 (ja) 2019-11-06
WO2015162532A1 (en) 2015-10-29
PT3134119T (pt) 2018-11-07
DK3134119T3 (en) 2018-10-22
CN106233143A (zh) 2016-12-14
RU2651469C1 (ru) 2018-04-19
EP3134119B1 (en) 2018-08-22
US20170184602A1 (en) 2017-06-29
KR20160134817A (ko) 2016-11-23
SG11201607918TA (en) 2016-11-29
BR112016024143A2 (pt) 2017-08-15
EP3134119A1 (en) 2017-03-01
CA2946362C (en) 2019-03-12
TR201815682T4 (tr) 2018-11-21
IL247859A0 (en) 2016-11-30
ES2691213T3 (es) 2018-11-26
AU2018203086A1 (en) 2018-05-24
HK1231561A1 (zh) 2017-12-22
HUE040167T2 (hu) 2019-02-28
TW201545747A (zh) 2015-12-16
AU2020200237A1 (en) 2020-02-06
US20190331687A1 (en) 2019-10-31
CN106233143B (zh) 2020-01-21
CA2946362A1 (en) 2015-10-29
AU2015249513A1 (en) 2016-10-06
MX375794B (es) 2025-03-07
AR100169A1 (es) 2016-09-14

Similar Documents

Publication Publication Date Title
MX2016013910A (es) Tratamiento del cancer.
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
CY1124879T1 (el) Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
UY36325A (es) Paneles del gen mutante del fgfr para identificar cánceres sensibles al tratamiento con un inhibidor del fgfr
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
PE20151893A1 (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
MX2015014486A (es) Marcadores de respuesta de células tumorales a la terapia.
MX383494B (es) Ácidos nucleicos libres de células para el análisis del microbioma humano y componentes del mismo.
ECSP13013084A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
IL270974A (en) Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
MX2018009254A (es) Metodos para evaluar el riesgo de desarrollar cancer colorrectal.
MX392040B (es) Estandares de antigeno prostatico y sus usos.
IL245936A0 (en) Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers
IL316167A (en) Methods for diagnosing and treating patients with cutaneous squamous cell carcinoma
SV2017005459A (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX362049B (es) Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
EP3596467C0 (en) DETECTION, QUANTIFICATION AND/OR ISOLATION OF CIRCULATING TUMOR CELLS BASED ON THE EXPRESSION OF THE CD321 MARKER
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.

Legal Events

Date Code Title Description
FG Grant or registration